PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Severe Cardiotoxicity in a Patient with Colorectal Cancer Treated with Bevacizumab.

Abstract Bevacizumab combined with standard chemotherapeutics has become a choice of treatment for several kinds of cancers. Hypertension, third-degree albuminuria, thrombosis and cardiotoxicity are the reported side-effects of bevacizumab. Among them, cardiotoxicity is a most severe, but rare outcome. We report a case of a 62-year-old female with colorectal carcinoma who was given bevacizumab-containing chemotherapy for more than 20 months and achieved a stable disease during the entire course of treatment. Thereafter, she developed cardiotoxicity including grade 3 hypertension, tricuspid regurgitation, pulmonary hypertension, left ventricular diastolic dysfunction and pericardial effusion, and was discontinued from the regimen with bevacizumab.
PMID
Related Publications

Bevacizumab safety in Japanese patients with colorectal cancer.

Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab.

Thromboembolic disease in advanced colorectal cancer treated with chemotherapy and bevacizumab: a case of real "pan-thrombosis".

A phase II study of bevacizumab with modified OPTIMOX1 as first-line therapy for metastatic colorectal cancer: the TCOG-GI 0802 study.

When a good call leads to a bad connection: colovesical fistula in colorectal cancer treated with bevacizumab.

Authors

Mayor MeshTerms
Keywords

Bevacizumab

cardiotoxicity

colorectal cancer

Journal Title anticancer research
Publication Year Start




PMID- 28739752
OWN - NLM
STAT- MEDLINE
DA  - 20170725
DCOM- 20170803
LR  - 20170803
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 37
IP  - 8
DP  - 2017 Aug
TI  - Severe Cardiotoxicity in a Patient with Colorectal Cancer Treated with
      Bevacizumab.
PG  - 4557-4561
AB  - BACKGROUND/AIM: Bevacizumab combined with standard chemotherapeutics has become a
      choice of treatment for several kinds of cancers. Hypertension, third-degree
      albuminuria, thrombosis and cardiotoxicity are the reported side-effects of
      bevacizumab. Among them, cardiotoxicity is a most severe, but rare outcome. We
      report a case of a 62-year-old female with colorectal carcinoma who was given
      bevacizumab-containing chemotherapy for more than 20 months and achieved a stable
      disease during the entire course of treatment. Thereafter, she developed
      cardiotoxicity including grade 3 hypertension, tricuspid regurgitation, pulmonary
      hypertension, left ventricular diastolic dysfunction and pericardial effusion,
      and was discontinued from the regimen with bevacizumab. CONCLUSION: Although
      clinically-effective, the severe cardiotoxicity of bevacizumab developed after
      over 20 courses of treatment prompted us to look for optimal chemotherapy
      prescription in order to achieve a better clinical outcome.
CI  - Copyright(c) 2017, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Chen, Jian
AU  - Chen J
AD  - Department of Oncology, the Affiliated Yantai Yuhuangding Hospital of Qingdao
      University, Yantai, P.R. China.
AD  - The Central Laboratory, the Affiliated Yantai Yuhuangding Hospital of Qingdao
      University, Yantai, P.R. China.
FAU - DU, Fengcai
AU  - DU F
AD  - The First Clinical College of DaLian Medical University, Dalian, P.R. China.
FAU - Hu, Baohong
AU  - Hu B
AD  - Department of Oncology, the Affiliated Yantai Yuhuangding Hospital of Qingdao
      University, Yantai, P.R. China.
FAU - Chi, Cheng
AU  - Chi C
AD  - Department of Oncology, the Affiliated Yantai Yuhuangding Hospital of Qingdao
      University, Yantai, P.R. China.
FAU - Chu, Hongjin
AU  - Chu H
AD  - The Central Laboratory, the Affiliated Yantai Yuhuangding Hospital of Qingdao
      University, Yantai, P.R. China.
FAU - Jiang, Lixin
AU  - Jiang L
AD  - Department of Gastrointestinal Surgery, the Affiliated Yantai Yuhuangding
      Hospital of Qingdao University, Yantai, P.R. China.
FAU - Li, Peng
AU  - Li P
AD  - Department of Oncology, the Affiliated Yantai Yuhuangding Hospital of Qingdao
      University, Yantai, P.R. China.
FAU - Gong, Zhaohua
AU  - Gong Z
AD  - Department of Oncology, the Affiliated Yantai Yuhuangding Hospital of Qingdao
      University, Yantai, P.R. China [email protected]
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biomarkers)
RN  - 2S9ZZM9Q9V (Bevacizumab)
SB  - IM
MH  - Angiogenesis Inhibitors/*adverse effects
MH  - Antineoplastic Agents/*adverse effects
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Bevacizumab/*adverse effects
MH  - Biomarkers
MH  - Biopsy
MH  - Cardiotoxicity
MH  - Colonoscopy
MH  - Colorectal Neoplasms/*complications/diagnosis/drug therapy
MH  - Female
MH  - Heart Diseases/diagnosis/*etiology
MH  - Humans
MH  - Middle Aged
MH  - Tomography, X-Ray Computed
OTO - NOTNLM
OT  - Bevacizumab
OT  - cardiotoxicity
OT  - colorectal cancer
EDAT- 2017/07/26 06:00
MHDA- 2017/08/05 06:00
CRDT- 2017/07/26 06:00
PHST- 2017/04/06 [received]
PHST- 2017/05/25 [revised]
PHST- 2017/05/27 [accepted]
AID - 37/8/4557 [pii]
PST - ppublish
SO  - Anticancer Res. 2017 Aug;37(8):4557-4561.